Martin I C
Acta Psychiatr Scand. 1975 Feb;51(2):110-8. doi: 10.1111/j.1600-0447.1975.tb00220.x.
A study of anti-Parkinsonism agents in prolonged phenothiazine therapy seeks to clarify some anecdotal misconceptions. Antiparkinsonian agents do not appear to affect the therapeutic efficiency of phenothiazines, nor does using them on a "demand" basis increase the problems of control of parkinsonian side effects. Older patients, however, appear to require the extended usage of antiparkinsonian agents rather more than some studies would suggest. Sustained release antiparkinsonian agents may yet further simplify the management of schizophrenia.
一项关于长期使用吩噻嗪类药物治疗时抗帕金森病药物的研究旨在澄清一些传闻中的误解。抗帕金森病药物似乎不会影响吩噻嗪类药物的治疗效果，而且按需使用这些药物也不会增加帕金森病副作用的控制问题。然而，老年患者似乎比一些研究所表明的更需要长期使用抗帕金森病药物。缓释抗帕金森病药物可能会进一步简化精神分裂症的治疗管理。
